Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Overview of multiple myeloma: the hematopoietic tumor treatment guideline [Internet]. Japanese Soc. Hematol. 2018 [cited 2020 Jun 5]. Available from: http://www.jshem.or.jp/gui-hemali/3_1.html
2. Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, et al. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). Int J Hematol. 2019;109:509–38.
3. Philip J, Sarkar RS, Pathak A. Adverse events associated with apheresis procedures: incidence and relative frequency. Asian J Transfus Sci. 2013;7:37–41.
4. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114:1729–35.
5. Iida S, Ishida T, Horimoto K, Kazama H, Kim H, Crawford B, et al. Medical database analysis of japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST)—a focus on healthcare resource utilization and cost. Int J Hematol. 2021;113:271–8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献